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Acceptance and rejection: Cost-effectiveness and the working
nephrologist.
While many nephrologists have developed a sophisticated
approach to appraising clinical trials, an equal comfort in cri-
tiquing cost-effectiveness literature is often lagging. Readers
can wonder how new results compare to those from other cost-
effectiveness trials, and whether they should accept a new inter-
vention as cost-effective or reject it as too costly for the benefit
it produces.
Critical readers should first judge whether the authors have
made the correct trade-off between complexity and generaliz-
ability when selecting a study perspective, and should exam-
ine the method of linkage between costs and effectiveness. The
most popular method is the incremental cost-effectiveness ra-
tio (ICER), which has limitations that have led some authors to
prefer the net monetary benefit (NMB), where confidence in-
tervals are more easily determined and which can more readily
be used in regression analyses. Interpretation of the ICER and
NMB require the choice of a cost-effectiveness ceiling, repre-
senting the maximum that society would be willing to pay for
an incremental health benefit, and the development of a deci-
sion rule based on this maximum. Comparing cost-effectiveness
studies from different disciplines requires the use of “universal”
effectiveness measures, such as the quality-adjusted life-year
(QALY).
An understanding of study perspective, the relative strengths
of different cost-effectiveness measures, the methods for mea-
suring uncertainty in these estimates, and how to select and use
cost-effectiveness ceiling ratios will help the critical reader to
determine if a new intervention should be accepted or rejected.
Restoring and preserving health is a pricey enterprise.
The costs and effectiveness of an intervention are factors
that must be balanced by physicians when prescribing an
intervention, and by health care planners when consider-
ing how to allocate resources between programs. Health
economics can guide medical decision making through
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analysis of the relative costs and outcomes of the relevant
options. While nephrologists are aware that dialysis is
expensive (and often quoted as a benchmark when
considering whether therapies are cost-effective), many
are uncomfortable appraising the results of a health
economics study. Readers are often left with concerns
such as “What is the meaning of the estimate of cost-
effectiveness? How confident are the authors in their re-
sults? How do I compare these results to those from other
cost-effectiveness studies? Should this new intervention
be accepted as cost-effective or rejected as too costly for
the incremental health benefit it provides?” We will ad-
dress these questions by focusing on concepts important
to the critical reading of studies that link costs and out-
comes, and interpreting these studies through the use of
decision rules. These issues are of particular importance
in nephrology, as dialysis is expensive, repetitive, ongoing,
and statutory.
We will build on previous works introducing the con-
cepts of cost-effectiveness analysis by familiarizing read-
ers with the recent methods to quantify uncertainty in
cost-effectiveness estimates, including the net monetary
benefit framework, by highlighting cost-effectiveness is-
sues from studies in nephrology, and by examining the
development of decision rules as a critical step in the anal-
ysis process. While many cost-effectiveness analyses are
performed using modeling techniques, we will focus on
studies that where costs and health benefits have been di-
rectly measured. Readers desiring a greater understand-
ing of costing methodologies, measuring effectiveness or
standards in health economics are directed to existing
works [1–9].
GETTING SOME PERSPECTIVE
An essential decision for an economic analysis is which
perspective to use when measuring costs and outcomes.
Options include the viewpoint of a patient, a hospital, a
health care provider organization [such as a health main-
tenance organization (HMO) or a provincial Ministry of
Health], or society as a whole. While analyses based on
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Fig. 1. Categories of cost-effectiveness analyses by type of effective-
ness measure. QALY is quality-adjusted life-year.
narrow perspectives are often easier to perform (as they
focus on fewer components), they may miss important
costs. For example, discharging a patient early from hos-
pital may reduce costs from the unit manager’s perspec-
tive but not for the health insurer, who must consider
increased costs related to home care. A “societal” per-
spective would be the broadest, including potentially im-
portant costs such as an informal caregiver’s lost wages.
Similarly, limited perspectives may exclude important
health outcomes. For example, a program of intensive
dialysis may reduce the requirement for antihyperten-
sives, but also improve sexual function (important from
the patient’s perspective) and restore social functioning
(important from the societal perspective).
It is important that the perspective taken be the same
for both costs and health outcomes. A study should not
capture health outcomes from a societal perspective,
while restricting costs to those borne by the dialysis unit.
As we will see later, the chosen perspective will also af-
fect how we judge which interventions are cost-effective
and which are not.
Guidelines for conducting economic analyses gener-
ally favor using broad perspectives, particularly the soci-
etal perspective [2, 10], although this can increase study
complexity, and require measurement of some costs and
outcomes that are difficult to quantify. The critical reader
should judge whether the authors have made the correct
trade-off between complexity and generalizability when
selecting a perspective.
RELATING COSTS AND OUTCOMES
It is rare for costing studies to be published without
a comparison of effectiveness, as cost-minimization is
rarely the primary aim of medical interventions [2]. Cost-
effectiveness analyses describe the impact of an inter-
vention on both costs and patient outcomes. The term
“cost-effectiveness study” is, somewhat confusingly, used
in two contexts: generically, to refer to any study that
links costs and outcomes (Fig. 1) and specifically, to re-
fer to studies that measure effectiveness with a “natural
unit,” an outcome that intuitively captures the effect of an
intervention. Examples of natural unit analyses include
studies that related the cost of OKT3 to the number of
years of graft survival ($8335/year of additional graft sur-
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Fig. 2. Equations used to estimate cost-effectiveness by calculating an
incremental cost-effectiveness ratio or net monetary benefit. Adapted
from Hoch JS, et al: Health Econ 11:415–430, 2002.
vival) [11], the cost of vaccination in predialysis clinics to
the number of cases of hepatitis B prevented ($856/case)
[12], and the cost of erythropoietin alpha to improvement
in hematocrit ($370/hematocrit percent) [13].
When the difference in costs is divided by the difference
in effectiveness, the result is one of the most commonly
used metrics in health economics, the incremental cost-
effectiveness ratio (ICER) (Fig. 2) [14], which is often
plotted in one of the quadrants of a cost-effectiveness
plane (Fig. 3) [15]. Consider an analysis that calculates
the ICER for a new therapy relative to the current stan-
dard of care. A new therapy both more effective and less
costly than conventional care (a “dominant” and there-
fore usually preferred therapy) is plotted in the southeast
quadrant, while one more costly and less effective (and
therefore usually rejected) is plotted in the northwest
quadrant. Many new interventions land in the northeast
quadrant (more effective but also more expensive). As
we will see, these require the development of a “decision
rule” before being accepted or rejected. Interventions in
the southwest quadrant cost are both less costly and less
effective than the standard of care. Acceptance or rejec-
tion of such an intervention will be a difficult decision,
as patients must sacrifice health in order to realize the
savings [16].
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The popularity of the ICER is partially due to its intu-
itive nature. We are faced daily with purchase decisions
where we choose between purchasing a cheaper product,
or a more expensive one that is in some way superior to its
less expensive brethren. Although intuitive, we will see
that the ICER has limitations, particularly when quanti-
fying uncertainty in cost-effectiveness estimates.
THE GREAT EQUALIZERS
Cost-effectiveness can be used as a measure of techni-
cal efficiency, which deals with the selection of the most
cost-effective approach to a medical problem, or to de-
termine allocative efficiency, which considers how best
to use scarce resources. Allocative efficiency is particu-
larly important for health policy decision makers consid-
ering decisions within the health care sector [for example,
to build a new dialysis unit or fund a new medication
for human immunodeficiency virus (HIV)], or between
health and other sectors (for example, to build a new
dialysis unit or a new high school). Analysts using cost-
effectiveness studies to assess allocative efficiency must
be able to compare results across studies; that is, there
must be standard measures of effectiveness. How would
a health care provider chose between OKT3 to prevent
rejection or hepatitis B vaccination in the predialysis set-
ting, assuming that budget constraints forced a choice be-
tween them? While both studies examined the technical
efficiency of the interventions, the dissimilarity in their
outcome measures prevents an easy comparison. Cost-
benefit and cost-utility studies are two types of economic
analyses that attempt to address this issue by incorporat-
ing “universal” effectiveness measures.
In cost-benefit analyses, the benefit of an intervention
is expressed in dollars. For example, a study concluded
that screening dialysis patients for iron deficiency with a
transferrin saturation saved $5 per dollar spent on screen-
ing by reducing erythropoietin use [17]. While the ex-
pression of benefit in monetary terms may be intuitive,
cost-benefit trials are uncommon in health care due to
methodologic issues (it is difficult to assign a dollar value
to some health states), moral dilemmas (some respon-
dents say that “you can’t put a price on health”), and
ethical concerns (the use of monetary valuations can bias
results in favor of those with more money) [18]. For these
reasons, cost-utility studies are a more popular alterna-
tive. Cost-utility studies measure effectiveness through
the use of utility scores, which reflect a person’s prefer-
ence for health states [19]. In health economics, utilities
are usually expressed on a scale ranging from 0 (a health
state equivalent to death) to 1 (equivalent to the best
imaginable health). Discussion of how utility scores are
measured can be found elsewhere [1, 2]. Cost-utility stud-
ies often express results using the popular outcome of
quality-adjusted life-years (QALYs), which are the prod-
uct of the utility score and the number of years spent in the
health state, and therefore simultaneously capture both
quantity and quality of life in a single measure. Studies
measuring cost-per-QALY permit the direct comparison
of studies from disparate medical fields.
TO ACCEPT OR REJECT: USING THE
COST-EFFECTIVENESS CEILING RATIO
If both costs and effectiveness are higher with a new
intervention, the question becomes whether the increase
in effectiveness is worth the extra expense, or colloqui-
ally, do we get enough bang for the buck? To answer this
question we need a “decision rule,” a guiding principle
(preferably prespecified) that defines the circumstances
where we will accept a new intervention as cost-effective.
For example, when considering antirejection therapy fol-
lowing renal transplantation, we might create a decision
rule stating that any new drug costing less than $10,000
per year of additional graft survival is cost-effective. De-
cision rules can be used to serve other purposes, such as
determining whether a new treatment should be funded,
however, we will restrict our discussion to the use of de-
cision rules in determining which of the available options
is the most cost-effective. Developing decision rules re-
quires us to know the maximum amount that the payer
would be willing to spend for an additional benefit. If
the intervention’s ICER is less than this maximum, the
new intervention is deemed cost-effective; otherwise it is
rejected as too costly for the benefit achieved. This maxi-
mum willingness to pay for a benefit is known as the cost-
effectiveness ceiling ratio, which can be plotted as a line
through the origin on the cost-effectiveness plane (Fig. 3).
Interventions falling on or to the right of this line are gen-
erally considered cost-effective, while those falling to the
left are not. While theoretic work justifies the existence
of a maximum ceiling ratio [20], in practice it is difficult to
agree on what this value should be [21]. In our previous
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example, the use of OKT3 following a kidney transplant
costs an additional $8335 for each additional year of graft
survival [11]. A decision rule based on the ICER would
dictate that if society were willing to pay $10,000 or more
for a year of graft survival, then OKT3 would be cost-
effective; however, if society were willing to pay only
$5000 for a year of graft survival, OKT3 is economically
unattractive.
When creating a decision rule, how are we to know the
maximum amount a payer would be willing to pay for a
year of graft survival? What is preventing an author from
choosing a ceiling ratio that leads to favorable interpre-
tation of their conclusions [21]? Authors can reduce such
concerns by referencing previous work that has suggested
standards for ceiling ratios or by presenting their results
using a variety of ceiling ratios.
When using the first approach, the author can take ad-
vantage of a broader study perspective. Consider erythro-
poietin therapy for anemia associated with renal disease.
Erythropoietin costs $370 per percent increase in hemat-
ocrit [13]. However, as a society we have not defined how
much (if anything) we would be willing to pay to increase
hematocrit. Our determination of whether erythropoi-
etin therapy should be accepted or rejected requires
comparison of the study results to the cost-effectiveness
ceiling ratio, which in this case is undefined, making inter-
preting of this study difficult. But what if the perspective
were broadened to incorporate other outcome measures?
Erythropoietin has also been shown to improve quality
of life in dialysis patients, a valuable outcome for which
ceiling ratios ranging from $60,000 to $160,000/QALY
have been suggested [22–25]. Knowing this, we could
suggest a decision rule that anemia therapy must cost
less than $100,000 per QALY gained in order to be cost-
effective. In a recent study, when erythropoietin was used
to raise the hemoglobin from the 9.5 to 10.5 range to the
11.0 to 12.0 range, the ICER was $55,295/QALY. Rais-
ing the hemoglobin to higher values increased the ICER
to more than $600,000/QALY [26]. Armed with our de-
cision rule, we can conclude that erythropoietin is likely
cost-effective when raising hemoglobin to the 11.0 to 12.0
range, but not cost-effective when a higher hemoglobin
is targeted. When broad perspective outcomes such as
QALYs are used, we can begin to determine which clini-
cal scenarios are cost-effective.
Alternatively, authors can calculate the probability of
cost-effectiveness across a range of ceiling ratios, allowing
the astute reader to select a cost-effectiveness ceiling that
they feel is appropriate. When authors present the proba-
bility of cost-effectiveness across a range of ceiling ratios,
readers using different decision rules will be equally well
served. The major limitation of this approach is the lack
of a clear conclusion for inexperienced readers, who may
not be able to suggest a cost-effectiveness ceiling for an
intervention.
MEASURING UNCERTAINTY IN A
COST-EFFECTIVENESS STUDY
One of the most significant drawbacks of the ICER
relates to the mathematical difficulty in creating confi-
dence intervals for a ratio [27, 28]. Accordingly, ICERs
are often published with no accompanying assessment of
uncertainty, an event that would be considered extraordi-
nary in any other type of study! Authors often side-step
this concern by presenting confidence intervals for the
individual differences in costs and outcome, but not for
the ICER itself. Recently, several methods have been de-
veloped to estimate uncertainty for the ICER, including
techniques such as “bootstrapping,” where statistical pre-
cision is estimated by repetitively generating hypothetical
substudies through resampling (randomly selecting data
from the original data set) with replacement (allowing
each original patient to be sampled more than once). The
uncertainty regarding the ICER can be demonstrated
graphically by plotting each of these substudies on the
cost-effectiveness plane. If a significant proportion (for
example, 95%) fall on or to the right of the line represent-
ing the selected cost-effectiveness ceiling ratio, then one
can be suitably confident that the new intervention is cost-
effective. Another graphic approach is the construction
of a cost-effectiveness acceptability curve, in which the
probability that the new intervention is cost-effective is
presented as a function of the ceiling ratio [29]. The curve
is drawn by calculating the proportion of ICER points
(generated by bootstrap or decision analysis techniques)
that fall on or to the right of a series of cost-effectiveness
ceiling lines. As an example of these two graphic illus-
trations of uncertainty in ICER estimates, we can con-
sider recent work by our research group examining the
costs and effectiveness of home nocturnal hemodialysis
versus conventional in-center hemodialysis [30]. We de-
termined that home nocturnal hemodialysis was domi-
nant, with an ICER of $45,932 saved per QALY gained,
but for the reasons mentioned above we did not provide
confidence intervals for this result. To illustrate uncer-
tainty in our results we created 2500 hypothetical study
groups using a bootstrap technique, and plotted these on
the cost-effectiveness plane, along with an ellipse that en-
compassed 95% of data points, the boundaries of which
fell entirely to the right of the $50,000 cost-effectiveness
ceiling line (Fig. 4). We then determined the propor-
tion of ICER points that were cost-effective at a vari-
ety of ceiling ratios, and generated an acceptability curve
(Fig. 5).
While graphical techniques help illustrate the un-
certainty in ICER estimates, numeric estimates of
confidence intervals are also desirable. As we will see,
a newer measure of cost-effectiveness known as the net
monetary benefit (NMB) can provide these estimates,
and correct for other shortcomings of the ICER.
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MEASURING NET MONETARY BENEFIT
Although the ICER is popular and intuitive, it has
some shortcomings. Cost-effectiveness estimates gener-
ated from empiric data may need to be adjusted for
baseline differences between the groups, a not uncom-
mon occurrence in the nephrology literature where trials
are often relatively small. Such adjustments are often
performed with regression analyses, but ratio statistics
like the ICER do not lend themselves well to such an
approach [31]. Also, a quick review of an ICER can
be misleading, as an intervention that is less expensive
and more effective will generate a negative ICER, but
so will an intervention that is more expensive and less
effective. Clearly the interpretation of these two results
would be entirely different. Finally, while uncertainty in
the ICER estimate can be illustrated graphically, calcu-
lating it mathematically is difficult. Many of these defi-
ciencies can be avoided by using an approach based on
the concept of an NMB. The NMB is calculated by assign-
ing a monetary value to the incremental benefit achieved
(equal to the product of the cost-effectiveness ceiling ra-
tio for one unit of benefit and the number of units of ben-
efit achieved), and subtracting from this the incremental
cost of achieving the benefit (Fig. 2) [32]. A positive NMB
always implies that the additional value of a new therapy
is more than the extra cost, and therefore it should be
considered cost-effective. A negative NMB implies that
an intervention should be rejected, as its value is less than
the additional cost of the benefit. The NMB is well suited
for use in regression analyses, and confidence intervals
and tests of statistical significance can be determined us-
ing standard statistical tests. The major limitation of the
NMB approach is that it requires the analyst to explicitly
place a monetary value on health outcomes through the
selection of a cost-effectiveness ceiling ratio. If there is
controversy regarding which ceiling ratio to use, an ana-
lyst can choose to present a series of NMB values calcu-
lated using a range of cost-effectiveness ceiling ratios.
Returning to our comparison of home nocturnal and in-
center hemodialysis, we calculated the NMB over a range
of cost-effectiveness ceilings using a multivariate regres-
sion analysis that accounted for the independent effects
of age and the presence of cardiovascular disease. In all
cases, the NMB of home nocturnal hemodialysis was pos-
itive, implying that the value of the incremental benefit
exceeded the incremental costs. We concluded that home
nocturnal hemodialysis was cost-effective over a range of
cost-effectiveness ceilings from $0 (if society were only
willing to consider interventions that were cost-saving)
to $100,000 per QALY gained. The ability to calculate
the NMB using regression techniques helped us to ad-
dress criticism that the differences in cost-effectiveness
between the two study groups were related to demo-
graphic differences rather than the type of dialysis. The
ability to determine the probability of a positive NMB
over a wide range of cost-effectiveness ceiling ratios al-
lowed us to satisfy readers who believe the societal cost-
effective ceiling ratio is different from that which we had
presented in our primary analysis.
CONCLUSION
When reviewing a cost-effectiveness paper, the reader
must ultimately decide whether to accept a new inter-
vention as cost-effective, or reject it as too expensive for
the benefit gained. This determination is aided by con-
sideration of study design and perspective, the method of
relating costs and effectiveness, and most importantly, the
comparison of study results to a reasonable ceiling ratio
(Table 1). Those interested in a more detailed approach
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Table 1. Suggested steps in critiquing a cost-effectiveness analysis
Step 1: Study design and perspective
How methodologically rigorous was the study design? (in order of
preference)
Meta-analysis of randomized controlled trials, randomized
controlled trial, prospective cohort, retrospective cohort,
case-series
What population was studied (consider age, gender, comorbid
conditions, dialysis vintage, socioeconomic factors, country of
study)?
Was the study perspective explicitly described and sufficiently broad?
(in order of preference)
Societal, health care payor [example, Minstry of Health, health
maintenance organization (HMO)], regional/multicenter
program, single hospital, single program (example, dialysis unit
or transplant program)
Did the list of costs and benefits studied match the selected
perpective?
Were the list of costs and benefits sufficiently broad to capture
important differences in costs and benefits of the studied
interventions?
Step 2: Relating costs and benefits
Were confidence intervals provided for the individual estimates of
differences in costs and effectiveness?
Which measure was used to relate costs and benefits?
For incremental cost-effectiveness ratios (ICER)
Was an estimate of the uncertainty in the ICER provided?
For Net Monetary Benefit (NBM)
Was an estimate of the uncertainty in the NMB provided?
Was a linear regression model testing the effect of baseline and
demographic variables on NMB presented?
Were sensitivity analyses provided that test the effect of critical
variables on the robustness of primary results?
Step 3: Interpreting the results
Was a predefined decision rule explicitly stated?
Is this cost-effectiveness measure compared against a
cost-effectiveness ceiling ratio?
Do the authors provide convincing justification for their choice of
ceiling ratios?
Does the reader agree with the chosen cost-effectiveness ceiling
ratio?
Was an estimate of probability of cost-effectiveness at the chosen
threshold provided?
Were estimates of probability of cost-effectiveness at different ceiling
ratios provided (example, a cost-effectiveness acceptability
curve)?
to reviewing cost-effectiveness studies are directed to the
“User’s Guide” series in the Journal of the American Med-
ical Association [6–8, 33, 34].
The push toward evidence-based practice has resulted
in many health professionals being able to critique clini-
cal trials with confidence and sophistication. These skills
form the first step in critiquing a health economics pa-
per. A familiarity with the methodology and terminology
used in cost-effectiveness analyses completes the skill set
needed to review these papers and to determine whether
new interventions should be accepted or rejected. As
cost-effectiveness studies appear more often in main-
stream medical journals, readers should develop the ex-
pertise required to appraise these works with confidence.
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